Hanseatic Management Services Inc. bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,997 shares of the company’s stock, valued at approximately $774,000.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech in the fourth quarter worth $34,000. Sound Income Strategies LLC boosted its position in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the last quarter. UMB Bank n.a. grew its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares in the last quarter. Global Retirement Partners LLC grew its stake in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Krystal Biotech in the 3rd quarter worth about $35,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
Krystal Biotech Price Performance
Krystal Biotech stock opened at $354.86 on Friday. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $382.54. The company’s fifty day moving average price is $331.38 and its two-hundred day moving average price is $289.47. The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of 47.44 and a beta of 0.50.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Citigroup raised their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Wolfe Research started coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $360.67.
Check Out Our Latest Stock Analysis on Krystal Biotech
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,642 shares of company stock worth $8,243,923 over the last three months. 13.10% of the stock is owned by company insiders.
About Krystal Biotech
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
